Post-COVID-19 severe neutropenia

Pediatr Blood Cancer. 2021 May;68(5):e28866. doi: 10.1002/pbc.28866. Epub 2020 Dec 23.

Authors

Boutheina Bouslama¹, Clément Pierret², Fatima Khelfaoui², Christine Bellanné-Chantelot³, Jean Donadieu⁴, Sébastien Héritier⁴

Affiliations

¹ Laboratory of Haematology, AP-HP, Hôpital Armand Trousseau, DMU BioGeM, Paris, France.
² General Pediatrics Department, Hôpital Saint Camille, Bry-sur-Marne, France.
³ Department of Genetics, AP-HP, Hôpital Pitié-Salpêtrière, DMU BioGeM, Paris, France.
⁴ Pediatric Hematology and Oncology Department, AP-HP, Hôpital Armand Trousseau, DMU ORIGYNE, Sorbonne Université, Paris, France.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Viral / blood
COVID-19 / pathology*
Filgrastim / therapeutic use*
Hematologic Agents / therapeutic use*
Humans
Immunoglobulin G / blood
Immunoglobulin M / blood
Infant
Leukocyte Count
Male
Neutropenia / drug therapy*
Neutropenia / pathology
Neutropenia / virology*
Neutrophils / cytology
SARS-CoV-2

Substances

Antibodies, Viral
Hematologic Agents
Immunoglobulin G
Immunoglobulin M
Filgrastim